Diamonds and Dogs


Synergy Pharmaceuticals, Inc. (SGYP)

Synergy is up $3.01 to $7.65 by mid-afternoon today, marking a 64.87% increase on the day. The company attributes this spike to the announcement of its drug plecanatide, and its success in relieving chronic idiopathic constipation (CIC). The drug, tested against a placebo, yielded a durable response of 41.5% of the population tested combining the results of two differing doses of plecanatide. I won't go into too much detail on how the drug goes about working, but just know that relief is soon to follow its ingestion. The drug formulated by Synergy only caused a side effect in 6% of its users, much lower than expected, and better than the 16% with side effects from Ironwood Pharmaceutical's (IRWD) "Linzess."


DAVIDsTEA marked another down day following the release of their first quarter earnings. The company is down $6.93 to $22.25. This 23.59% drop, was added to the sharp decline occurring after market close yesterday evening. The company's first quarter net loss of C$93.2 million (approximately 75.8 million USD) was tied to the stronger US Dollar as well as investment in its supply chain. The company is relatively new to the public, only obtaining its IPO June 5th, so the tank on earnings does not foreshadow its shutdown. The company says its earnings were most hurt by one-time costs related to going public.  

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.